Popular Weight Loss Drugs May Pose Mental Health Risks, Says New Study
Popular weight loss drugs such as Ozempic and Mounjaro belong to a class of drugs called GLP-1 receptor agonists, which work by mimicking the hormone incretin. GLP-1 receptor agonists are commonly prescribed for type-2 diabetes.
These popular weight loss drugs may contribute to some common side effects such as nausea, vomiting, diarrhea, constipation, stomach pain and fatigue. Vision loss, thyroid tumours, kidney problems, gallbladder issues and pancreatitis are some of the concerning side effects users may face.
A new study has highlighted the mental health risks associated with GLP-1 receptor agonists. The study published in Current Neuropharmacology uncovers links between GLP-1 agonists and genes associated with mood regulation, depression, and suicidal ideation. The study also highlights that GLP-1 agonists may benefit some individuals with hyperdopaminergic (excess dopamine activity), but they could be harmful to those with hypodopaminergic (low dopamine function).
These drugs affect genes such as DRD3, BDNF, and CREB1, which play key roles in mood and reward pathways.
"Chronic use may disrupt dopamine signaling and increase the risk of depression and suicidal thoughts," researchers highlight.
"This study should not be ignored, despite the hype surrounding the positive clinical outcomes of GLP1 receptor agonists," said senior author Dr. Kenneth Blum of Western University Health Sciences and Ariel University.
"The paper provides critical evidence for reevaluating the widespread use of GLP1 receptor agonists. The FDA and other regulatory agencies should carefully consider our findings when it comes to labeling and monitoring these drugs," Dr. Mark S. Gold, an addiction psychiatry pioneer and co-author, emphasized.
For the unversed, these drugs mimic GLP-1, a hormone naturally produced in the gut when you eat and plays a role in regulating blood sugar, appetite, and digestion. It interacts with GLP-1 receptors in the brain, particularly in areas controlling hunger and satiety. This helps reduce appetite and increases the feeling of fullness after eating.
Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
15 hours ago
- India Today
European drugs regulator flags rare eye risk with Ozempic
The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, the regulator said on EMA, which started its review in December, said the use of the drugs is linked to about twofold increase in the risk of developing the condition compared to people not taking the medicine. NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after have linked semaglutide to NAION in the past. But this is the first time a regulator has made the belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness.A large study of nearly 350,000 diabetics published earlier this year had showed that the risk of developing NAION more than doubled after long-term use of semaglutide, compared to patients taking medicines from other EMA said it has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials and has recommended the drugmaker to update prescribing information for medicines containing semaglutide to include NAION as a side effect with a frequency of "very rare".The US Food and Drug Administration did not immediately respond to a Reuters request for Watch
Time of India
15 hours ago
- Time of India
FDA shuts 3 food businesses at Patradevi, Margao
Panaji: The food and drugs administration (FDA) directed two food business operators—a restaurant and a cashew shop—to suspend operations at Patradevi, Pernem, due to unhygienic conditions. The FDA inspected 18 outlets at Patradevi, issued improvement notices, and gave them 14 days to comply. They seized Rs 50,000 worth of food items, including chips, chocolates, and dry fruits with artificial colours. Samples of sweets were also taken for testing. The FDA also directed a restaurant in Margao to shut down for failing to pay a fine and for non-compliance with FDA directions following its inspection on April 28. They found that only 5 of 30 deficiencies were addressed and ordered the food operator to stop all activities and submit a compliance report. Get the latest lifestyle updates on Times of India, along with Eid wishes , messages , and quotes !
Hans India
16 hours ago
- Hans India
Alzheimer's gene therapy shows promise to prevent brain damage
New Delhi: A novel gene therapy for Alzheimer's disease, which showed promise to protect the brain from damage and preserve cognitive function, has renewed hope for millions of patients with the neurodegenerative disease. Worldwide, approximately 57 million people live with dementia, and Alzheimer's disease is the most common cause, accounting for 60-70 per cent of cases. Alzheimer's occurs when abnormal proteins build up in the brain, leading to the death of brain cells and declines in cognitive function and memory. While current treatments can manage symptoms of Alzheimer's, the new gene therapy aims to halt or even reverse disease progression, said researchers from the University of California San Diego School of Medicine. They noted that, unlike existing treatments for Alzheimer's that target unhealthy protein deposits in the brain, the new approach could help address the root cause of Alzheimer's disease by influencing the behaviour of brain cells themselves. The study investigated the effect of hippocampal SynCav1 delivery in two distinct preclinical mice models. The results, published in the journal Signal Transduction and Targeted Therapy, showed that delivering the treatment at the symptomatic stage of the disease preserved hippocampal-dependent memory -- a critical aspect of cognitive function that is often impaired in Alzheimer's patients. Further, the finding stated that compared to healthy mice of the same age, the treated mice also had a similar pattern of gene expression. This suggests that the treatment has the potential to alter the behaviour of diseased cells to restore them to a healthier state. 'While multiple newly FDA-approved treatments focus on targeting amyloid-beta clearance in Alzheimer's patients, the therapeutic value of SynCav1 lies in its ability to protect vulnerable neurons and augment cellular responses -- mechanisms that differ from currently approved therapies,' said the researchers in the paper. Due to the multitude of neurotoxicity in the Alzheimer's brain, the team called for further studies to investigate SynCav1's therapeutic role when combined with amyloid-targeted drugs to enhance clinical outcomes.
